drugset / Trial / NCT02791815

Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects

NCT02791815

Phase 1 Completed 20 enrolled Actelion
RandomizedCrossoverOpen-label

Summary

The primary purpose of this study is to evaluate the effect of repeated doses of selexipag on the pharmacokinetics of a single oral dose of midazolam (i.e., how long and how much midazolam is present in the blood)

Timeline

Start
2016-07
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 7.5 mg Oral
Subject Selexipag Small molecule 1600 ug Oral

Indications

No indication recorded.